HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

Benzinga · 2d ago
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $28 to $31.